ArticleRespirology case reports2025
Combined IVIG and High-Dose Systemic Corticosteroids for the Management of Pembrolizumab-Induced Cytokine Release Syndrome in Lung Adenocarcinoma.
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Immune checkpoint inhibitors-related cytokine storm syndrome: a systematic review of characteristics, treatment, and outcomes.Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe a case of a 61-year-old woman with stage IV lung adenocarcinoma (cT4N0M1a) and contralateral lung metastases who developed immune-related adverse events (irAEs) following the 8th maintenance cycle of pembrolizumab and pemetrexed. Despite initiating systemic corticosteroids, her condition rapidly deteriorated into multiple organ dysfunction syndrome with elevated interleukin-6 (IL-6) levels. Tocilizumab was administered for suspected cytokine release syndrome (CRS) but resulted in minimal improvement. However, the subsequent administration of combined intravenous immunoglobulin (IVIG) and high-dose systemic corticosteroids led to gradual recovery, and she was ultimately discharged in a stable condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.